Download presentation
Presentation is loading. Please wait.
Published byNathan Dickerson Modified over 9 years ago
1
Evaluation of home-based management of fever in urban Ugandan children Sarah Staedke London School of Hygiene & Tropical Medicine MU-UCSF Research Collaboration
2
Home-based management of fever (HBMF) HBMF has been advocated to promote prompt appropriate treatment of malaria In Uganda, HBMF has been launched Pre-packaged CQ+SP (Homapak) Community drug distributors Presumptive treatment of febrile children Plans to introduce AL into HBMF in Uganda No data on the use of ACTs for HBMF are available Studies only with CQ, mostly seasonal transmission
3
Study objectives To evaluate the utility of HBMF using AL in a cohort of children in Kampala By comparing outcomes in children whose households were provided with AL to those from households without this intervention Aim to evaluate the impact of HBMF vs. current standard of care for management of childhood fever on clinical outcomes and economic measures
4
Study procedures Children aged 1-5 years recruited from Mulago III parish Households completing pilot period were randomized to: HBMF: Households educated and given AL to keep at home for presumptive treatment of fever in participating children Standard care: Households instructed to continue their current approach to management of childhood illness Clinical and laboratory evaluations At baseline, start, mid-point, and end of intervention Household diaries, monthly questionnaires Information on illnesses, treatment-seeking behavior Visits to health care facilities, health care expenditures
5
HBMF COHORT Home-based care STANDARD CARE 212 children 159 households HBMF AL at home 225 children 166 households Target population = Mulago III parish U01 COHORT Health facility- based care 601 children (1-10y)
6
Primary outcome Treatment incidence density In U01, treatments for lab-confirmed cases of malaria In Standard care and HBMF, treatments for fever/malaria
7
Prompt appropriate therapy Incidence of treatments Standard careHBMFP-value Including an appropriate antimalarial* 0.984.31< 0.0001 Given within 24 hours (prompt) 1.893.55< 0.0001 Prompt appropriate antimalarial 0.172.43< 0.0001 Antibiotic treatment2.402.090.180 HBMF → increase in prompt and appropriate antimalarial therapy * Appropriate antimalarial → CQ+SP, quinine, Coartem, artemisinins
8
Summary Results on HBMF in Kampala are mixed (+) Marked improvement in drug delivery (+) Modest clinical benefit (–) Substantial over-treatment Delay in treatment seeking for non-malarial illnesses Over-treatment may drive drug resistance (–) Less cost-effective Future directions Similar study comparing health facility-based treatment to HBMF with AL vs. DP in Tororo Funded by Gates / ACT Consortium
9
Thanks Christopher Whitty Gates Malaria Partnership Phil, Grant, Moses Norah and HBMF team
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.